Literature DB >> 25183075

Rapid detection of MDR-Mycobacterium tuberculosis using modified PCR-SSCP from clinical Specimens.

Imani Fooladi Abbas Ali1, Farzam Babak2, Mousavi Seyed Fazlollah3, Jonaidi Jafari Nematollah4.   

Abstract

OBJECTIVE: To design a rapid test to detect the rifampin (RIF) and isoniazid (INH) resistant mutant based on polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) technique that analyzes the katG, rpoB genes.
METHODS: Biochemical test as well as IS6110 targeting PCR revealed 103 clinical samples were tuberculosis. To determine the susceptibility of isolates to anti TB drugs, the proportional method was used. Mutations presented within the amplified products of the katG, rpoB genes were evaluated by SSCP.
RESULTS: Using proportional method, 12 (11.6%) and 9 (8.7%) isolates were resistant respectively to INH and RIF and 9 (8.7%) isolates showed resistance to both drug (multi-drug resistant tuberculosis). Three (2.9%) multi-drug resistant tuberculosis and two INH resistant isolates were detected by the PCR-SSCP and sequencing. The sensitivity and specificity of PCR-SSCP for multi-drug resistant isolates were 33% and 100%, respectively.
CONCLUSIONS: Complete agreement between SSCP and sequencing can indicate that resistance-associated mutations have occurred in other genes except our considered genes.

Entities:  

Keywords:  Drug resistance; Mycobacterium tuberculosis; PCR-SSCP; Phenotypic method; katG; rpoB

Year:  2014        PMID: 25183075      PMCID: PMC4025311          DOI: 10.12980/APJTB.4.2014C1186

Source DB:  PubMed          Journal:  Asian Pac J Trop Biomed        ISSN: 2221-1691


  25 in total

1.  Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India.

Authors:  A Nusrath Unissa; N Selvakumar; Sujatha Narayanan; P R Narayanan
Journal:  Int J Antimicrob Agents       Date:  2007-11-14       Impact factor: 5.283

2.  Drug resistance of Mycobacterium tuberculosis strains in southern Brazil.

Authors:  Laynara Katize Grutzmacher; Eduardo Monguilhott Dalmarco; Solange Lucia Blatt; Caio Mauricio Mendes de Cordova
Journal:  Rev Soc Bras Med Trop       Date:  2012-02       Impact factor: 1.581

3.  Diagnostic potential of IS6110, 38kDa, 65kDa and 85B sequence-based polymerase chain reaction in the diagnosis of Mycobacterium tuberculosis in clinical samples.

Authors:  S S Negi; R Anand; S T Pasha; S Gupta; S F Basir; S Khare; S Lal
Journal:  Indian J Med Microbiol       Date:  2007-01       Impact factor: 0.985

4.  Simultaneous detection of isoniazid, rifampin, and ethambutol resistance of Mycobacterium tuberculosis by a single multiplex allele-specific polymerase chain reaction (PCR) assay.

Authors:  Zhenhua Yang; Riza Durmaz; Dong Yang; Selami Gunal; Lixin Zhang; Betsy Foxman; Ahmet Sanic; Carl F Marrs
Journal:  Diagn Microbiol Infect Dis       Date:  2005-10-21       Impact factor: 2.803

5.  Study of resistance to anti-tuberculosis drugs in five districts of Equatorial Guinea: rates, risk factors, genotyping of gene mutations and molecular epidemiology.

Authors:  G Tudó; J González; R Obama; J M Rodríguez; J R Franco; M Espasa; P R Simarro; G Escaramís; C Ascaso; A García; M T Jiménez de Anta
Journal:  Int J Tuberc Lung Dis       Date:  2004-01       Impact factor: 2.373

6.  Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan.

Authors:  Joveria Qais Farooqi; Erum Khan; Syed Muhammed Zaheer Alam; Asho Ali; Zahra Hasan; Rumina Hasan
Journal:  J Pak Med Assoc       Date:  2012-08       Impact factor: 0.781

7.  Mass-spectrometry based minisequencing method for the rapid detection of drug resistance in Mycobacterium tuberculosis.

Authors:  Larisa N Ikryannikova; Maxim V Afanas'ev; Tat'yana A Akopian; Elena N Il'ina; Aleksey V Kuz'min; Elena E Larionova; Tat'yana G Smirnova; Larisa N Chernousova; Vadim M Govorun
Journal:  J Microbiol Methods       Date:  2007-05-31       Impact factor: 2.363

8.  Variations in the occurrence of specific rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis isolates from patients of different ethnic groups in Kuwait.

Authors:  Suhail Ahmad; Noura M Al-Mutairi; Eiman Mokaddas
Journal:  Indian J Med Res       Date:  2012-05       Impact factor: 2.375

Review 9.  Tuberculosis: From an incurable scourge to a curable disease - journey over a millennium.

Authors:  Surendra K Sharma; Alladi Mohan
Journal:  Indian J Med Res       Date:  2013-03       Impact factor: 2.375

Review 10.  Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation.

Authors:  Francis Drobniewski; Vladyslav Nikolayevskyy; Horst Maxeiner; Yanina Balabanova; Nicola Casali; Irina Kontsevaya; Olga Ignatyeva
Journal:  BMC Med       Date:  2013-08-29       Impact factor: 8.775

View more
  4 in total

1.  Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.

Authors:  Siavash J Valafar
Journal:  Antimicrob Agents Chemother       Date:  2021-02-17       Impact factor: 5.191

Review 2.  First-Line Anti-Tubercular Drug Resistance of Mycobacterium tuberculosis in IRAN: A Systematic Review.

Authors:  Babak Pourakbari; Setareh Mamishi; Mona Mohammadzadeh; Shima Mahmoudi
Journal:  Front Microbiol       Date:  2016-07-28       Impact factor: 5.640

3.  Use of DNA microarray chips for the rapid detection of Mycobacterium tuberculosis resistance to rifampicin and isoniazid.

Authors:  Peijun Tang; Xiafang Wang; Xinghua Shen; Meihua Shi; Xuefeng Zhu; Xin Yu; Jia Liu; Chunhua Ling; Meiying Wu
Journal:  Exp Ther Med       Date:  2017-03-21       Impact factor: 2.447

Review 4.  An updated systematic review and meta-analysis on Mycobacterium tuberculosis antibiotic resistance in Iran (2013-2020).

Authors:  Farzad Khademi; Amirhossein Sahebkar
Journal:  Iran J Basic Med Sci       Date:  2021-04       Impact factor: 2.699

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.